Thank you! Ocrevus and Kesimpta will remain on the PBS
17 July 2026
The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments.Â
MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS
16 July 2026
MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).
PBS access to two vital MS treatments under threat as Government decision looms
1 July 2026
Multiple disease-modifying therapies (DMTs), Ocrevus (ocrelizumab) and Kesimpta (ofatumumab), are at risk of being withdrawn from the Pharmaceutical Benefits Scheme (PBS), as a consequence of government-driven policy-related price reductions.
Thank you! Ocrevus and Kesimpta will remain on the PBS
17 July 2026
The Australian Government has confirmed that Ocrevus and Kesimpta will remain available through the Pharmaceutical Benefits Scheme (PBS), meaning thousands of Australians living with MS can continue to access these life-changing treatments.Â
MS Australia applauds Health Minister’s announcement that Ocrevus and Kesimpta will remain on the PBS
16 July 2026
MS Australia warmly welcomes the announcement from the Minister for Health and Aged Care, the Hon Mark Butler MP, that Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) will remain available through the Pharmaceutical Benefits Scheme (PBS).
